Janzer, R.C.

patient radiotherapy temozolomide survival glioblastoma trial treatment cancer study group tumor analysis prognostic gbm-o oncol glioma bene fit fication oligodendroglioma-like component mutation status outcome eortc signi table phase research methylation factor number feature component review neuropathol university month necrosis adjuvant temozolomide idh 1 mutations analyses 5 years class promoter chemotherapy presence value subtype glioblastoma multiforme mgmt methylation status brain therapy diagnosis classi classi fication adjuvant pathology van den tumour survival group surgery signi ficantly centre 1·0 lausanne university hospital effect lausanne treatment effect stupp expression identi idh 1 ampli firmed methylated progression resection 2 years randomised criteria department